 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 861980
Online Users : 138
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/2843
|
| Title: | Low-dose thalidomide treatment for advanced hepatocellular carcinoma |
| Authors: | Hsu, C;Chen, CN;Chen, LT;Wu, CY;Yang, PM;Lai, MY;Lee, PH;Cheng, AL |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Objective: To analyze the efficacy of oral thalidomide in the treatment of advanced hepatocellular carcinoma ( HCC). Methods: Sixty- eight patients with unresectable and nonembolizable HCC were consecutively enrolled in a compassionate treatment program of oral thalidomide. Tumor response and treatment- related toxicity were prospectively followed. Thalidomide was given at a starting dose of 200 mg per day. The dose was gradually escalated in 100- mg steps up to 600 mg per day if no limiting toxicities developed. Results: Sixty- three patients were evaluable for response. One complete and 3 partial responses, defined by World Health Organization criteria, were seen, with a response rate of 6.3% ( 95% CI 0 - 12.5). The duration of response was 50+, 24.6, 11.6+ and 8.7+ weeks, respectively. All 4 responders had a dramatic decrease in alpha- fetoprotein ( alpha- FP) levels. Another 6 of the 42 patients with elevated alpha- FP levels before treatment had a more than 50% decrease in their alpha- FP levels after thalidomide treatment. Totally 10 patients had an objective response to thalidomide. The median overall survival for all of the 68 patients was 18.7 weeks ( 95% CI 11.8 - 25.6) with a 1- year survival rate of 27.6%. The median overall survival of the 10 patients with an objective response to thalidomide was 62.4 weeks ( 95% CI 31.2 - 93.6 weeks). All responders responded at a dose equal to or less than 300 mg per day. Toxicities of thalidomide were generally manageable, and only 16, 6, and 0 patients developed grade 2, 3, and 4 toxicities, respectively. Conclusion: Low- dose thalidomide is safe and induces unequivocal tumor response in a minority of patients with advanced HCC. |
| Keywords: | Oncology |
| Date: | 2003 |
| Relation: | Oncology. 2003;65(3):242-249. |
| Link to: | http://dx.doi.org/10.1159/000074477 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0030-2414&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000186975500008 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0344305652 |
| Appears in Collections: | [陳立宗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 000186975500008.pdf | | 216Kb | Adobe PDF | 379 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
